Actively Recruiting
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Led by Stephanie B. Seminara, MD · Updated on 2026-03-31
40
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
Sponsors
S
Stephanie B. Seminara, MD
Lead Sponsor
E
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin. This study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characterization of endogenous LH secretion before and after kisspeptin administration. This frequency of blood sampling is required to define the features of LH pulses.
CONDITIONS
Official Title
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 to 45 years or Male aged 18 to 60 years
- Normal blood pressure (systolic less than 140 mm Hg and diastolic less than 90 mm Hg)
- Hemoglobin level no less than 0.5 g/dL below the lower limit of the sex-specific reference range
- No current or recent use of medications affecting the reproductive axis or willing to complete a medication washout
- For women, negative serum hCG pregnancy test
- For cases, diagnosis of post-COVID-19 syndrome
- For controls, history of prior COVID infection but no post-COVID-19 syndrome diagnosis
You will not qualify if you...
- Any medical, mental, or behavioral condition likely to interfere with study participation
- Excessive alcohol consumption (more than 10 drinks per week)
- Active use of illicit drugs
- For women, pregnant, trying to become pregnant during the study, or breastfeeding
- History of bilateral oophorectomy, breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
S
Study Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here